Blog

Frier Levitt Adds Pharmacist-Attorney Martha M. Rumore as Senior Counsel

Frier Levitt, LLC, a national boutique healthcare and life sciences law firm, announced today that Martha M. Rumore Pharm.D., Esq., has joined the firm as a Senior Counsel. She will be working out of Frier Levitt's New York City office. Dr. Rumore has over 15 years of legal experience focused on healthcare law; Food, Drug Cosmetic law; pharmacy regulatory issues; PBM issues; and insurance related matters, as well as pharmaceutical...

Frier Levitt’s Government Affairs/Advocacy Services

As legal counsel to providers in an ever-changing healthcare landscape, Frier Levitt recognizes the importance of monitoring proposed, pending and recently enacted legislation and/or rulemaking that affects our clients. From time-to-time, stakeholders are invited to participate in shaping the outcome of a proposed bill (perhaps though testimony at a Congressional hearing) or a proposed rule (through the submission of a public comment to be considered by a rulemaking agency.) We...

CMS Seeking Public Comments on Reforming Scope of Practice Regulations

Acting on Executive Order #13890, "Protecting and Improving Medicare for Our Nation's Seniors," the Centers for Medicare & Medicaid Services ("CMS") will consider new regulations designed to eliminate the regulatory barriers that constrain advanced practice providers (i.e., physician assistants and advanced practice nurses) from practicing at the top of their professional licenses. These barriers include burdensome billing requirements, conditions of participation, and supervision requirements that are more stringent than applicable...

New Jersey Law Grants Rights to Pharmacies Against PBM Post-Adjudication Fees and Mailing Prohibitions

On December 19, 2019, NJ Governor, Phil Murphy, signed into law an important new bill regulating PBMs, effective on March 18, 2020. The bill, A3717, passed with unanimous support in both legislative houses, amends the State’s current PBM regulations and outlaws post-adjudication fees by PBMs, such that: "After the date of receipt of a clean claim for payment made by a pharmacy, a pharmacy benefits manager shall not retroactively reduce...

PHARMACY ALERT: New Year = New P&Ps for Pharmacies

Recently, a former Aegerion Pharmaceuticals Inc. salesman, Mark Moffett, was found guilty, by a federal jury, of conducting a drug fraud scheme that cost Medicare and other insurers more than $1.8 million. According to federal prosecutors, Moffett faked patient histories, diagnoses and certain test results, all in an effort to cause claims for Aegerion's cholesterol treatment, Juxtapid, to be approved by payors, including PBMs. While Moffett had argued that any...